Analytical Tool - Hematological Cancers

  • ID: 356346
  • March 2014
  • Region: Global
  • Bioseeker
1 of 3

"Analytical Tool – Hematological Cancers" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in hematological cancers. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool provides you with an immense amount of information structured and analyzed to assist you in your work. It is designed to assist you in finding right partners, optimizing your licensing deals, wisely choosing which projects give you the best competitive advantage, and assuring you that your decisions have been based on the most accurate, validated and precise facts available.

Included in this advantageous package are three products already appreciated by many of our customers:

A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Hematological Cancers READ MORE >

Note: Product cover images may vary from those shown
2 of 3

1 Executive Summary

2 Methodology

3 List of Contents

3.1 List of Boxes
3.2 List of Tables

4 The Lymphomas

4.1 Introduction
4.1.1 Disease Definition
4.1.2 Etiology & Pathophysiology
4.2 Epidemiology
4.3 Current Treatment Strategies
4.3.1 Hodgkins Disease
4.3.2 Radiation Therapy
4.3.3 Chemotherapy
4.3.4 Transplantation
4.3.5 Treatment Option Overview
4.4 Non-Hodgkins Lymphoma
4.4.1 Radiation Therapy
4.4.2 Chemotherapy
4.4.3 Immunotherapy
4.4.4 Bone Marrow and Peripheral Blood Transplants
4.4.5 Watch and Wait
4.4.6 Treatment Option Overview
4.5 Prognosis
4.5.1 Hodgkins Disease
4.5.2 Non-Hodgkin
4.6 Progress in Current Treatment Strategies
4.6.1 Hodgkin
4.6.2 Non-Hodgkin
4.6.3 Rituxan
4.6.4 Bexxar
4.6.5 Zevalin
4.7 Key Therapeutic Strategies for Future Treatments
4.7.1 Therapy Type, Targets & Mechanisms
4.8 Competitive Landscape in Drug Development: The Late Stage Pipeline
4.9 Current Drug Development: The Early Stage Pipeline

5 The Leukemias

5.1 Introduction
5.1.1 Disease Definitions
5.1.2 Etiology & Pathophysiology
5.1.3 The Lymphoid Malignancies
5.1.4 The Myeloid Malignancies
5.2 Epidemiology
5.3 Prognosis
5.3.1 The Lymphoid Malignancies
5.3.2 The Myeloid Malignancies
5.4 Current Treatment Strategies
5.4.1 The Lymphoid Malignancies
5.4.2 The Myeloid Malignancies
5.5 Progress in Current Treatment Strategies
5.5.1 The Lymphoid Malignancies
5.5.2 The Myeloid Malignancies
5.6 Key Therapeutic Strategies for Future Therapies
5.6.1 Therapeutic Type, Targets & Mechanisms
5.7 Competitive Landscape in Drug Development: The Late Stage Pipeline
5.7.1 The Lymphoid Malignancies
5.7.2 The Myeloid Malignancies
5.8 Current Drug Development: The Early Stage Pipeline
5.8.1 The Myeloid Malignancies
5.8.2 The Lymphoid Malignancies
5.9 Disclaimer
5.9.1 Liability
5.9.2 Completeness

6 Appendix: Drugs Approved for the Treatment of Leukemia: a Historical Perspective

7 Drug Index

8 Company Index

3.1 List of Boxes

Box 1: Possible Complications of Treatment
68HBox 2: Updated REAL/WHO Classification for B-Cell Neoplasms
69HBox 3: Subclassification of Stage
70HBox 4: Updated REAL/WHO Classification for B-Cell Neoplasms
71HBox 5: Updated REAL/WHO Classification for T-Cell and Putative NK-Cell Neoplasms
72HBox 6: Staging Subclassification System
73HBox 7 Study Details
74HBox 8: Major Treatment Regimes
75HBox 9: CLL Staging System
76HBox 10: Quick Facts - Clofarabine
7HBox 11: Quick Facts - Alemtuzumab
78HBox 12: Quick Facts - Gemtuzumab
79HBox 13: Quick Facts - Imatinib
80HBox 14: Quick Facts - Rituximab
81HBox 15: Quick Facts - Genasense
82HBox 16: Quick Facts - Flavopiridol
83HBox 17: Quick Facts - Atra
84HBox 18: Quick Facts - Gvax
85HBox 19: Quick Facts - Zarnestra
86HBox 20: Quick Facts - BAY 43-9006
Box 21: Quick Facts - Ceplene
Box 22: Quick Facts - Valspodar
Box 23: Quick Facts - CEP-701
Box 24: Quick Facts - PKC412
Box 25: Quick Facts - SU5416
Box 26: Quick Facts - PTK787
Box 27: Quick Facts - Cloretazine
Box 28: Company Statement on Progress
Box 29: Quick Facts - Troxacitabine
Box 30: Quick Facts - FK228
Box 31: Quick Facts - Decitabine
Box 32: Quick Facts - VELCADE
Box 33: Velcade Sales 2005
Box 34: Quick Facts - AG-858
Box 35: Quick Facts - Avastin
Box 36: Quick Facts - OSI-461
Box 37: Quick Facts - Xcytrin
Box 38: Quick Facts - AP23573

3.2 List of Tables

Table 1: Drugs Used in the Treatment of Lymphoma
Table 2 Summary of Strategies Enhancing Antibody Function
Table 3 Cancer Immunotherapy Strategies
Table 4: Protein Kinase Targets in Clinical Trials for Lymphoma
Table 5: Near Term Progress Aldesleukin
Table 6: Near Term Progress Arsenic trioxide
Table 7: Near Term Progress BiovaxID
Table 8: Near Term Progress Bortezomib
Table 9: Near Term Progress Epratuzumab
Table 10: Near Term Progress FavId
Table 11: Near Term Progress MyVax
Table 12: Near Term Progress Nelarabine
Table 13: Near Term Progress Genasense
Table 14: Near Term Progress Pixantrone
Table 15: Near Term Progress Temsirolimus
Table 16: Near Term Progress Zanolimumab
Table 17: Near Term Progress Flavopiridol
Table 18: Near Term Progress Bevacizumab
Table 19: Near Term Progress CMC-544
Table 20: Near Term Progress Galiximab
Table 21: Near Term Progress LY317615
Table 22: Near Term Progress SGN-40
Table 23: Near Term Progress Apolizumab
Table 24: Near Term Progress SGN-30
Table 25: ALL Classification
Table 26: Latest Approved Drugs for the Treatment of Leukemia
Table 27: Kinase Inhibitors in Development for the Treatment of Leukemia
Table 28: Near Term Progress Rituximab
Table 29: Near Term Progress Oblimersen
Table 30: Near Term Progress Alvocidib
Table 31: Near Term Progress ATRA
Table 32: Near term progress GVAX
Table 33: Near tearm progress HuM195
Table 34: Near term progress Zarnestra
Table 35: Near Term Progress Sorafenib
Table 36: Near Term Progress Valspodar
Table 37: Summary of Current Late Stage Pipeline
Table 38: Near term progress CEP-701
Table 39: Near Term Progress PKC412
Table 40: Near Term Progress SU5416
Table 41: Near Term Progress PTK787
Table 42: Near Term Progress VNP40101M
Table 43: Near Term Progress Troxacitabine
Table 44: Near Term Progress Decitabine
Table 45 Near Term Progress Bortezomib
Table 46 Near Term Progress AG-858
Table 47: Near Term Progress Bevacizumab
Table 48: Near Term Progress OSI-461
Table 49: Near Term Progress Xcytrin
Table 50: Near Term Progress AP23573
Table 51: Summary of Current Early Stage Pipeline

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown


  • Quick Help: The report will be emailed to you. Updates are supplied for this report during the year. This is a single user license, allowing one specific user access to the product.


If you have a more general question about our products please try our



Our Clients

  • Photocure ASA
  • Roche Diagnostics Ltd.
  • Abbott Laboratories Ltd.
  • Pfizer, Inc.
  • Novartis AG
  • Becton, Dickinson and Company (BD)